They have found that the malignant gliomas harboring MDMX amplification and overexpression have neither p53 mutation nor MDM2 amplification, supporting the role of MDMX in helping gliomas escape from p53-dependent growth control (57, 58). Here, MDM4 is linked to central nervous system cancer.